Opendata, web and dolomites

MAGELIA SIGNED

A disruptive Magnetically Enhanced Library preparation platform for Next Generation Sequencing

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAGELIA project word cloud

Explore the words cloud of the MAGELIA project. It provides you a very rough idea of what is the project "MAGELIA" about.

tool    instrument    accelerating    institut    clinicians    france    biologists    grants    accelerate    holds    ignite    succeed    tackle    times    rights    miniaturised    confirmed    generation    engineers    ready    business    platforms    ten    expensive    paris    larger    cheaper    entirely    board    reproducibility    faster    2021    trl8    preparations    earlier    medium    miniaturized    patents    series    400    raw    advisory    companies    curie    backed    breaking    preparation    finish    persons    2016    genomics    microfluidics    exclusive    market    sme    billion    sequencing    scarce    seed    meet    reagents    samples    initiate    automated    ngs    inorevia    inception    platform    modern    democratise    awards    pharmacy    upstream    first    biotech    trl6    put    round    biology    smaller    labs    magelia    won    leverages    spin    cnrs    talents    scientists    customers    manual    medicine    struggle    library    throughput    15    volumes    biological    commercialization    secured    prototype    leader    fast    revolution    company    renowned    turnover    off    team    ground    1000   

Project "MAGELIA" data sheet

The following table provides information about the project.

Coordinator
INOREVIA 

Organization address
address: 6 RUE JEAN CALVIN
city: PARIS
postcode: 75005
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙000 €
 EC max contribution 1˙955˙100 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INOREVIA FR (PARIS) coordinator 1˙955˙100.00

Map

 Project objective

Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform. After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market. To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round. The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGELIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGELIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

LOLAS (2019)

Precise and reliable autonomous landing for drones, helicopters and other rotorcraft

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More